Immunotherapy in leukaemia

Acta Clinica Belgica

Volumn 67, Issue 6, 2012, Pages 399-402

  Van De Velde, A L R ^a,b   Anguille, S ^a,b   Berneman, Z N ^a,b  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Cancer; Dendritic cells; Immunotherapy; Leukaemia; Vaccine

Indexed keywords

DENDRITIC CELL VACCINE; SIPULEUCEL T; CANCER VACCINE;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CONFERENCE PAPER; HUMAN; IMMUNE SYSTEM; NONHUMAN; PROSTATE CANCER; ANTIGEN PRESENTING CELL; DENDRITIC CELL; EVIDENCE BASED MEDICINE; FORECASTING; IMMUNOLOGY; IMMUNOTHERAPY; LEUKEMIA; METHODOLOGY; NATURAL KILLER CELL; REVIEW; RISK FACTOR; T LYMPHOCYTE;

ANTIGEN-PRESENTING CELLS; CANCER VACCINES; DENDRITIC CELLS; EVIDENCE-BASED MEDICINE; FORECASTING; HUMANS; IMMUNOTHERAPY; KILLER CELLS, NATURAL; LEUKEMIA; RISK FACTORS; T-LYMPHOCYTES;

MLCS; MLOWN;

EID: 84874808178     PISSN: 00015512     EISSN: None     Source Type: Journal    
DOI: 10.2143/ACB.67.6.2062703     Document Type: Conference Paper

References (15)

1. http://www.eiu.com/site-info.asp?info-name=LAF&page=noads (Accessed 2012 July 9).
2. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012; 12: 265-277.
3. Anguille S, Lion E, Smits E, Berneman ZN, van Tendeloo VF. Dendritic cell vaccine therapy for acute myeloid leukemia: questions and answers. Hum Vaccin 2011; 7: 579-584.
4. Anguille S, Van Tendeloo VF, Berneman ZN. Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia. Leukemia 2012.
5. Anguille S, Willemen Y, Lion E, Smits EL, Berneman ZN. Dendritic cell vaccination in acute myeloid leukemia. Cytotherapy 2012; 14: 647-656.
6. Van de Velde AL, Berneman ZN, Van Tendeloo VF. Immunotherapy of hemato-logical malignancies using dendritic cells. Bull Cancer. 2008 Mar; 95(3): 320-326. (Pubitemid 351528769)
7. VanTendeloo VF, VandeVelde A, deVries IJ, Sugiyama H, Berneman ZN. Induc-tion of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination. Proc Natl Acad Sci U S A. 2010 Aug 3; 107(31): 13824-13829.
8. Anguille S, Van Tendeloo V, Berneman Z. Dendritic cell-based therapeutic vac-cination for acute myeloid leukemia. Bull Cancer 2012; 99: 635-642.
9. Finn OJ. Cancer immunology. N Engl J Med 2008; 358: 2704-2715.
10. Schadendorf D, Ugurel S, Schuler-Thurner B, et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: A randomized phase III trial of the DC study group of the DeCOG. Ann Oncol 2006; 17: 563-570.
11. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castra-tion-resistant prostate cancer. N Engl J Med 2010; 363: 411-422.
12. Karan D, Holzbeierlein JM, Van Veldhuizen P, Thrasher JB. Cancer immunother-apy: A paradigm shift for prostate cancer treatment. Nat Rev Urol 2012.
13. Berneman ZN. Autologous T cells on the attack against AML. Blood. 2012; 120(6): 1151-1152.
14. Anguille S, Smits EL, Cools N, Goossens H, Berneman ZN, Van Tendeloo VF. Short-term cultured, interleukin-15 differentiated dendritic cells have potent immunostimulatory properties. J Transl Med 2009; 7: 109.
15. Schlom J, Arlen PM, Gulley JL. Cancer vaccines: moving beyond current para-digms. Clin Cancer Res 2007; 13: 3776-3782. (Pubitemid 47037581)